Skip to content
Evevident
Original paper
2021NEJMInfectious Disease

RECOVERY dexamethasone

Dexamethasone in Hospitalized Patients with Covid-19

RCTCOVID / critical care

On this page

Overview

Dexamethasone reduced mortality in hospitalized COVID-19 patients requiring oxygen or mechanical ventilation, but not in those without oxygen requirement.

Clinical takeaway

RECOVERY dexamethasone established steroids as standard therapy for hypoxic COVID-19 and clarified that benefit is tied to inflammatory/hypoxemic disease stage.

Key result

28-day mortality was 22.9% with dexamethasone vs 25.7% with usual care (RR 0.83).

Practice impact

Use dexamethasone for COVID-19 patients requiring oxygen; avoid routine steroids in non-hypoxic COVID solely for antiviral-stage disease.

Evidence

Study design

Randomized, controlled, open-label platform trial.

Enrollment

6,425

Follow-up

28 days.

Geography

United Kingdom

Clinical question

Does dexamethasone reduce mortality in hospitalized COVID-19?

Population

  • Hospitalized patients with COVID-19 across respiratory-support strata (no oxygen, oxygen, invasive ventilation).

Intervention

Dexamethasone 6 mg daily (oral or IV) for up to 10 days plus usual care.

Comparator

Usual care alone.

Primary outcome

28-day mortality.

Dexamethasone lowered 28-day mortality in hospitalized COVID-19, with the largest benefit in ventilated patients and no benefit in those not needing oxygen.

Rate ratio / 0.83 / CI 95% CI 0.75-0.93 / p=<0.001

Key results

  • Overall 28-day mortality: 22.9% with dexamethasone vs 25.7% with usual care; RR 0.83 (95% CI 0.75-0.93; p<0.001).
  • Invasive mechanical ventilation: 29.3% vs 41.4%; RR 0.64.
  • Oxygen without ventilation: 23.3% vs 26.2%; RR 0.82.
  • No oxygen requirement: 17.8% vs 14.0%; RR 1.19, with no benefit and a possibility of harm.

Harms

  • No mortality benefit, and a signal toward harm, in patients not requiring oxygen.
  • Corticosteroids can cause hyperglycemia and, with prolonged use, secondary infection.

Clinical Use

When to cite

  • When deciding whether hospitalized patients with COVID-19 should receive corticosteroids based on oxygen requirement.

Practice impact

  • Use dexamethasone for COVID-19 patients requiring oxygen; avoid routine steroids in non-hypoxic COVID solely for antiviral-stage disease.

Applicability

  • Most applicable to hospitalized patients with COVID-19 who require supplemental oxygen or mechanical ventilation.

Limitations

  • Open-label design (though mortality is an objective endpoint).
  • Conducted early in the pandemic; variants, vaccination, and background therapies have since evolved.
  • Benefit depends on disease stage; results should not be extrapolated to non-hypoxic outpatients.

Common misinterpretations

  • Dexamethasone helps in the hyperinflammatory/hypoxemic phase, not early antiviral-phase disease without oxygen need.
  • The overall mortality reduction masks heterogeneity: large benefit if ventilated, none if not on oxygen.

Citation

RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021;384(8):693-704. doi:10.1056/NEJMoa2021436

In patients hospitalized with Covid-19, the use of dexamethasone resulted in lower 28-day mortality among those who were receiving either invasive mechanical ventilation or oxygen alone at randomization but not among those receiving no respiratory support.